Larimar Therapeutics, Inc. (LRMR)
2.97
-0.14
(-4.50%)
USD |
NASDAQ |
Feb 20, 15:36
Larimar Therapeutics EPS Diluted (Quarterly) : -0.6092 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.4206 |
| Agenus, Inc. | 1.944 |
| Alnylam Pharmaceuticals, Inc. | 1.368 |
| Savara, Inc. | -0.1366 |
| Arrowhead Pharmaceuticals, Inc. | 0.219 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -47.71M |
| Total Expenses (Quarterly) | 47.71M |
| Enterprise Value | 95.10M |
| Earnings Yield | -64.90% |
| Normalized Earnings Yield | -64.90 |